Inside America’s New Biotech Buildout

BioMADE directs federal funding to new facilities and workforce programmes as supply chain risks sharpen

20 Nov 2025

The United States is accelerating efforts to rebuild its biomanufacturing capacity, placing fermentation and other bioindustrial processes at the centre of a broader strategy to reduce supply chain exposure and strengthen domestic production.

BioMADE, the public-private group overseeing federal investments in the sector, set out its latest plans on April 29. It announced a demonstration-scale facility in Minnesota, backed by at least $132mn and expected to open around 2027. The site is intended to bridge the gap between laboratory research and commercial output-a stage that has often delayed the move from discovery to market.

The announcement follows BioMADE’s October 30 funding round, reported by some outlets on November 4. The group allocated $26.9mn to 17 projects aimed at expanding the bioindustrial ecosystem. The portfolio includes pilot-scale infrastructure, workforce training programmes and early-stage support designed to help companies validate their technologies and secure private investment.

Fermentation underpins production of therapeutic ingredients, specialty chemicals and advanced materials, but the US has struggled to keep pace with global rivals. Companies have relied on overseas facilities to meet demand, increasing exposure to delays and supply disruptions. Federal backing is rising as industry groups seek more reliable domestic options.

Analysts say future progress will depend on closer coordination among agencies, updated quality and safety systems, and continued investment in downstream processes, such as purification and finishing, that often determine whether new products can scale.

With new facilities in development and a clearer national strategy emerging, sector leaders describe a more optimistic outlook. If current momentum continues, US firms could gain greater speed, security and competitiveness in global biomanufacturing.